NCT07742527 clinical trial report covering Belantamab, Phase 1, endpoints, sponsor, geography, readout timing and development white space.

CTR20263007 clinical trial report covering SHR-7012, Phase 1, endpoints, sponsor, geography, readout timing and development white space.

ChiCTR2600129374 clinical trial report covering Relicpixant, Phase 1, endpoints, sponsor, geography, readout timing and development white space.

ChiCTR2600129382 clinical trial report covering TQH2722, Phase 1, endpoints, sponsor, geography, readout timing and development white space.

ChiCTR2600129420 clinical trial report covering HCXT-2001, Phase 1, endpoints, sponsor, geography, readout timing and development white space.

ChiCTR2600129396 clinical trial report covering HWS111, Phase 1, endpoints, sponsor, geography, readout timing and development white space.

NCT07745439 clinical trial report covering NTQ5082, Phase 1, endpoints, sponsor, geography, readout timing and development white space.

NCT07744243 clinical trial report covering SI-B036, Phase 1, endpoints, sponsor, geography, readout timing and development white space.

Abcuro, Inc. BD opportunity scan covering pipeline ownership, development stage, evidence package, IP risk, deal precedent and outreach rationale using PatSnap MCP.

NCT07746141 clinical trial report covering Tislelizumab, Phase 1, endpoints, sponsor, geography, readout timing and development white space.

NCT07744646 clinical trial report covering Alpha-0261, Phase 1, endpoints, sponsor, geography, readout timing and development white space.

NCT07744152 clinical trial report covering BI 3822971 (Boehringer Ingelheim GmbH), Phase 1, endpoints, sponsor, geography, readout timing and development w